EXHIBIT RR.1

UNITED STATES BANKRUPTCY COURT

SOUTHERN DISTRICT OF NEW YORK

----x

In Re: Cae No:

RESIDENTIAL CAPITAL, LLC, et. al, 12-12020(MG)

Debtors.

-----x

VIDEOTAPE DEPOSITION OF TIMOTHY DEVINE

New York, New York

November 19, 2012

10:17 a.m.

Reported by:

ERICA L. RUGGIERI, RPR

JOB NO: 27973

	Pg 3 of 6		
	102		104
1	TIMOTHY DEVINE	1	TIMOTHY DEVINE
2	period ended March 31, 2012. But I but	2	this exhibit it's all part of note 24,
3	I'm in no position to authenticate that	3	isn't it?
4	this document is what the front page of it	4	MR. PRINCI: Objection as to
5	indicates it is. That's not in my job.	5	form.
6	Q. It's already been authenticated,	6	A. Yeah, I don't know. I I
7	Mr. Devine. You saw the 10-Q at the time	7	I I guess it is.
8	it was filed?	8	Q. You guess it is.
9	A. I can't say I saw the 10-Q. I	9	A. I'm reading this with you right
10	probably saw parts of it.	10	now, okay?
11	Q. Did you participate in its	11	Q. Okay. And note 24 deals with
12	preparation?	12	contingencies and other risks; is that
13	A. I gave advice to the client in	13	correct?
14	connection with its preparation.	14	A. At this page that looks like it
15	Q. The 10-Q was filed on April 27,	15	might be page 66 there's a heading 24,
16	2012, right?	16	Contingencies and Other Risks.
17	A. I don't know.	17	Q. And among the contingencies
18	Q. Take a look at page 73.	18	addressed are loan repurchase obligations
19	A. Okay.	19	related to loan sales, correct?
20	Q. And directing your attention to	20	A. Where where are you looking?
21	the heading Potential Losses, Litigation	21	Q. On pages 68 and 69. One of the
22	Repurchase Obligations and Related Claims.	22	contingencies identified in note 24 is
23	Do you see that?	23	Loan Repurchases and Obligations Related
24 25	A. Yes.	24 25	to Loan Sales, right?
25	Q. Did you participate in the	+	A. That seems to be correct. I'm
	103		105
1	TIMOTHY DEVINE	1	TIMOTHY DEVINE
2	preparation of any of the material under	2	just reading this page 68 and that's
3	this heading?	3	that's what that heading says, Loan
4	A. Yes.	4	Repurchases and Obligations Related to
5	Q. The paragraphs under that	5	Loan Sales.
6	heading, until you get to the number 25	6	Q. Okay. And those obligations are
7	that says Subsequent Events, up until	7	described with a number of types of
8	that, those are part of note 24, which	8	transactions, including government
9	begins on page 66, correct?	9	sponsored enterprises or GSEs, right?
10	A. It may be a copying issue but I	10	A. Well, at this point you are
11	have a blank page at page 66.	11	asking me to characterize the structure
12	Q. Okay. On the other side of it.	12	and content of the document. And I'm just
13	On the other side of what appears on this	13	not in a position to do that.
14	copy of the exhibit to be a blank, you see	14	MR. BRYAN: Maybe if you could
15	the notes? This is all part of note 24,	15	direct the witness to a particular
16 17	right, that runs from that page, and it	16 17	part where there's a reference to
	doesn't have it's a copying error, the		GSEs, do it that way.
18 19	66 which is on the back. It runs from there to page 73. Can we agree on that?	18 19	Q. On the bottom of page 69 government sponsored enterprises are
20	A. I I what are we agreeing	20	listed as one category, are they not?
21	on, sorry?	21	A. What I can tell you is I see at
22	Q. That note 24 let's let's	22	the bottom of page 69 a paragraph
23	do it this way. That the material on page	23	beginning right at the bottom of the page,
24	73 up until you get to the note 25 begins	24	the heading of which is Government
25	on the page following page number 65 in	25	Sponsored Enterprises.
	on the page tono ming page number 05 in	T	Sponsored Enterprises.

	Pg 4 of 6		
	134		136
1	TIMOTHY DEVINE	1	TIMOTHY DEVINE
2	person who wrote it, but it appears to	2	of a defect rate of a nonloan level for
3	represent the information submitted as	3	those populations.
4	part of a fourth quarter 2011 CCAR	4	Q. Okay. And the next line under
5	submission.	5	Additional Items says "Potential
6	Q. Okay.	6	investor/securities litigation." Do you
7	A. And to include data projections	7	see that?
8	through 2013.	8	A. Yes, I see it.
9	Q. And then the additional items	9	Q. Is the amount shown for that
10	below adjusted that to make a presentation	10	item \$400 million, the estimate of
11	that ran through the first quarter of	11	exposure for securities fraud claims at
12	2012, correct?	12	that point?
13	A. Yes. If what you are asking is	13	A. No.
14	does this slide as a whole describe the	14	
l l		14 15	Q. Okay. What does it represent?
15 16	identified potential exposures as of first		A. As I sit here today, my memory
17	quarter 2012, the answer is yes.	16	is that it represents the estimated top
	Q. The first line under additional	17	end of the range of reasonably possible
18	items says "Estimated nonwrapped potential	18	losses for ResCap over time related to
19	exposure beyond 2013." What did that	19	litigation and repurchase obligation of
20	refer to?	20	related claims. Meaning, as I understand,
21	A. Well, I can tell you sitting	21	that would have been subject to certain
22	here today what, as I recall, what it	22	stresses beyond what the estimated
23	referred to.	23	exposure would have been.
24	Q. We can only ask for your	24	Q. Mr. Devine, I was only focusing
25	recollection, Mr. Devine.	25	on the line that says "Potential
	125		
	135		137
1	TIMOTHY DEVINE	1	TIMOTHY DEVINE
1 2		1 2	TIMOTHY DEVINE
	TIMOTHY DEVINE		
2	TIMOTHY DEVINE A. Okay. So as I recall sitting	2	TIMOTHY DEVINE investor/securities litigation." And
2 3	TIMOTHY DEVINE A. Okay. So as I recall sitting here today, the estimated nonwrapped	2 3	TIMOTHY DEVINE investor/securities litigation." And there's a \$400 million number next to that. Wasn't that some estimate of the
2 3 4	TIMOTHY DEVINE A. Okay. So as I recall sitting here today, the estimated nonwrapped potential exposure beyond 2013 represented	2 3 4	TIMOTHY DEVINE investor/securities litigation." And there's a \$400 million number next to that. Wasn't that some estimate of the possible or reasonably possible range of
2 3 4 5	TIMOTHY DEVINE A. Okay. So as I recall sitting here today, the estimated nonwrapped potential exposure beyond 2013 represented estimated lifetime losses, which I'm	2 3 4 5	TIMOTHY DEVINE investor/securities litigation." And there's a \$400 million number next to that. Wasn't that some estimate of the possible or reasonably possible range of loss for securities litigation?
2 3 4 5 6	TIMOTHY DEVINE A. Okay. So as I recall sitting here today, the estimated nonwrapped potential exposure beyond 2013 represented estimated lifetime losses, which I'm testing with the note here, multiplied by	2 3 4 5 6	TIMOTHY DEVINE investor/securities litigation." And there's a \$400 million number next to that. Wasn't that some estimate of the possible or reasonably possible range of loss for securities litigation? MR. BRYAN: Object to form.
2 3 4 5 6 7	TIMOTHY DEVINE A. Okay. So as I recall sitting here today, the estimated nonwrapped potential exposure beyond 2013 represented estimated lifetime losses, which I'm testing with the note here, multiplied by risks post fund audit defect rates	2 3 4 5 6 7	TIMOTHY DEVINE investor/securities litigation." And there's a \$400 million number next to that. Wasn't that some estimate of the possible or reasonably possible range of loss for securities litigation? MR. BRYAN: Object to form.
2 3 4 5 6 7 8	TIMOTHY DEVINE A. Okay. So as I recall sitting here today, the estimated nonwrapped potential exposure beyond 2013 represented estimated lifetime losses, which I'm testing with the note here, multiplied by risks post fund audit defect rates adjusted for litigation defenses. Risk	2 3 4 5 6 7 8	TIMOTHY DEVINE investor/securities litigation." And there's a \$400 million number next to that. Wasn't that some estimate of the possible or reasonably possible range of loss for securities litigation? MR. BRYAN: Object to form. A. Yeah. Well, there's a lot of detail behind that line. And as I sit
2 3 4 5 6 7 8 9	TIMOTHY DEVINE A. Okay. So as I recall sitting here today, the estimated nonwrapped potential exposure beyond 2013 represented estimated lifetime losses, which I'm testing with the note here, multiplied by risks post fund audit defect rates adjusted for litigation defenses. Risk referred to Todd Kushman's group. And so	2 3 4 5 6 7 8	TIMOTHY DEVINE investor/securities litigation." And there's a \$400 million number next to that. Wasn't that some estimate of the possible or reasonably possible range of loss for securities litigation? MR. BRYAN: Object to form. A. Yeah. Well, there's a lot of detail behind that line. And as I sit here today, I just can't remember the
2 3 4 5 6 7 8 9	TIMOTHY DEVINE A. Okay. So as I recall sitting here today, the estimated nonwrapped potential exposure beyond 2013 represented estimated lifetime losses, which I'm testing with the note here, multiplied by risks post fund audit defect rates adjusted for litigation defenses. Risk referred to Todd Kushman's group. And so that would have been what I don't	2 3 4 5 6 7 8 9	TIMOTHY DEVINE investor/securities litigation." And there's a \$400 million number next to that. Wasn't that some estimate of the possible or reasonably possible range of loss for securities litigation? MR. BRYAN: Object to form. A. Yeah. Well, there's a lot of detail behind that line. And as I sit here today, I just can't remember the detail. But as I recall, that would have
2 3 4 5 6 7 8 9 10	TIMOTHY DEVINE A. Okay. So as I recall sitting here today, the estimated nonwrapped potential exposure beyond 2013 represented estimated lifetime losses, which I'm testing with the note here, multiplied by risks post fund audit defect rates adjusted for litigation defenses. Risk referred to Todd Kushman's group. And so that would have been what I don't remember is nonwrapped potential exposure	2 3 4 5 6 7 8 9 10	TIMOTHY DEVINE investor/securities litigation." And there's a \$400 million number next to that. Wasn't that some estimate of the possible or reasonably possible range of loss for securities litigation? MR. BRYAN: Object to form. A. Yeah. Well, there's a lot of detail behind that line. And as I sit here today, I just can't remember the detail. But as I recall, that would have been a number subject to a variety of
2 3 4 5 6 7 8 9 10 11	TIMOTHY DEVINE A. Okay. So as I recall sitting here today, the estimated nonwrapped potential exposure beyond 2013 represented estimated lifetime losses, which I'm testing with the note here, multiplied by risks post fund audit defect rates adjusted for litigation defenses. Risk referred to Todd Kushman's group. And so that would have been what I don't remember is nonwrapped potential exposure beyond 2013, whether that would have included anything beyond private label	2 3 4 5 6 7 8 9 10 11 12	TIMOTHY DEVINE investor/securities litigation." And there's a \$400 million number next to that. Wasn't that some estimate of the possible or reasonably possible range of loss for securities litigation? MR. BRYAN: Object to form. A. Yeah. Well, there's a lot of detail behind that line. And as I sit here today, I just can't remember the detail. But as I recall, that would have been a number subject to a variety of stresses that were imposed on the process
2 3 4 5 6 7 8 9 10 11 12 13	TIMOTHY DEVINE A. Okay. So as I recall sitting here today, the estimated nonwrapped potential exposure beyond 2013 represented estimated lifetime losses, which I'm testing with the note here, multiplied by risks post fund audit defect rates adjusted for litigation defenses. Risk referred to Todd Kushman's group. And so that would have been what I don't remember is nonwrapped potential exposure beyond 2013, whether that would have included anything beyond private label securities nonwrapped potential exposure.	2 3 4 5 6 7 8 9 10 11 12 13	TIMOTHY DEVINE investor/securities litigation." And there's a \$400 million number next to that. Wasn't that some estimate of the possible or reasonably possible range of loss for securities litigation? MR. BRYAN: Object to form. A. Yeah. Well, there's a lot of detail behind that line. And as I sit here today, I just can't remember the detail. But as I recall, that would have been a number subject to a variety of stresses that were imposed on the process from outside of this sort of legal
2 3 4 5 6 7 8 9 10 11 12 13	TIMOTHY DEVINE A. Okay. So as I recall sitting here today, the estimated nonwrapped potential exposure beyond 2013 represented estimated lifetime losses, which I'm testing with the note here, multiplied by risks post fund audit defect rates adjusted for litigation defenses. Risk referred to Todd Kushman's group. And so that would have been what I don't remember is nonwrapped potential exposure beyond 2013, whether that would have included anything beyond private label	2 3 4 5 6 7 8 9 10 11 12 13 14	TIMOTHY DEVINE investor/securities litigation." And there's a \$400 million number next to that. Wasn't that some estimate of the possible or reasonably possible range of loss for securities litigation? MR. BRYAN: Object to form. A. Yeah. Well, there's a lot of detail behind that line. And as I sit here today, I just can't remember the detail. But as I recall, that would have been a number subject to a variety of stresses that were imposed on the process from outside of this sort of legal advisory function.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	TIMOTHY DEVINE A. Okay. So as I recall sitting here today, the estimated nonwrapped potential exposure beyond 2013 represented estimated lifetime losses, which I'm testing with the note here, multiplied by risks post fund audit defect rates adjusted for litigation defenses. Risk referred to Todd Kushman's group. And so that would have been what I don't remember is nonwrapped potential exposure beyond 2013, whether that would have included anything beyond private label securities nonwrapped potential exposure. I just don't remember. Q. The next line under Additional	2 3 4 5 6 7 8 9 10 11 12 13 14 15	TIMOTHY DEVINE investor/securities litigation." And there's a \$400 million number next to that. Wasn't that some estimate of the possible or reasonably possible range of loss for securities litigation? MR. BRYAN: Object to form. A. Yeah. Well, there's a lot of detail behind that line. And as I sit here today, I just can't remember the detail. But as I recall, that would have been a number subject to a variety of stresses that were imposed on the process from outside of this sort of legal advisory function. Q. Right. Okay.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. Okay. So as I recall sitting here today, the estimated nonwrapped potential exposure beyond 2013 represented estimated lifetime losses, which I'm testing with the note here, multiplied by risks post fund audit defect rates adjusted for litigation defenses. Risk referred to Todd Kushman's group. And so that would have been what I don't remember is nonwrapped potential exposure beyond 2013, whether that would have included anything beyond private label securities nonwrapped potential exposure. I just don't remember. Q. The next line under Additional Items says "Adj. for application of defect	2 3 4 5 6 7 8 9 0 1 1 2 3 4 1 5 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	rimothy devine investor/securities litigation." And there's a \$400 million number next to that. Wasn't that some estimate of the possible or reasonably possible range of loss for securities litigation? MR. BRYAN: Object to form. A. Yeah. Well, there's a lot of detail behind that line. And as I sit here today, I just can't remember the detail. But as I recall, that would have been a number subject to a variety of stresses that were imposed on the process from outside of this sort of legal advisory function. Q. Right. Okay. A. That's the more complete answer.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. Okay. So as I recall sitting here today, the estimated nonwrapped potential exposure beyond 2013 represented estimated lifetime losses, which I'm testing with the note here, multiplied by risks post fund audit defect rates adjusted for litigation defenses. Risk referred to Todd Kushman's group. And so that would have been what I don't remember is nonwrapped potential exposure beyond 2013, whether that would have included anything beyond private label securities nonwrapped potential exposure. I just don't remember. Q. The next line under Additional Items says "Adj. for application of defect rate at a nonloan level for nonwrapped PLS	234567890112345678	investor/securities litigation." And there's a \$400 million number next to that. Wasn't that some estimate of the possible or reasonably possible range of loss for securities litigation? MR. BRYAN: Object to form. A. Yeah. Well, there's a lot of detail behind that line. And as I sit here today, I just can't remember the detail. But as I recall, that would have been a number subject to a variety of stresses that were imposed on the process from outside of this sort of legal advisory function. Q. Right. Okay. A. That's the more complete answer. Q. Let me show you what's been
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	A. Okay. So as I recall sitting here today, the estimated nonwrapped potential exposure beyond 2013 represented estimated lifetime losses, which I'm testing with the note here, multiplied by risks post fund audit defect rates adjusted for litigation defenses. Risk referred to Todd Kushman's group. And so that would have been what I don't remember is nonwrapped potential exposure beyond 2013, whether that would have included anything beyond private label securities nonwrapped potential exposure. I just don't remember. Q. The next line under Additional Items says "Adj. for application of defect rate at a nonloan level for nonwrapped PLS and additional provision for wrapped PLS."	2345678901123456789	investor/securities litigation." And there's a \$400 million number next to that. Wasn't that some estimate of the possible or reasonably possible range of loss for securities litigation? MR. BRYAN: Object to form. A. Yeah. Well, there's a lot of detail behind that line. And as I sit here today, I just can't remember the detail. But as I recall, that would have been a number subject to a variety of stresses that were imposed on the process from outside of this sort of legal advisory function. Q. Right. Okay. A. That's the more complete answer. Q. Let me show you what's been marked previously as Exhibit 83.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. Okay. So as I recall sitting here today, the estimated nonwrapped potential exposure beyond 2013 represented estimated lifetime losses, which I'm testing with the note here, multiplied by risks post fund audit defect rates adjusted for litigation defenses. Risk referred to Todd Kushman's group. And so that would have been what I don't remember is nonwrapped potential exposure beyond 2013, whether that would have included anything beyond private label securities nonwrapped potential exposure. I just don't remember. Q. The next line under Additional Items says "Adj. for application of defect rate at a nonloan level for nonwrapped PLS and additional provision for wrapped PLS." Do you see that?	234567890112341567890	TIMOTHY DEVINE investor/securities litigation." And there's a \$400 million number next to that. Wasn't that some estimate of the possible or reasonably possible range of loss for securities litigation? MR. BRYAN: Object to form. A. Yeah. Well, there's a lot of detail behind that line. And as I sit here today, I just can't remember the detail. But as I recall, that would have been a number subject to a variety of stresses that were imposed on the process from outside of this sort of legal advisory function. Q. Right. Okay. A. That's the more complete answer. Q. Let me show you what's been marked previously as Exhibit 83. A. Thank you.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 6 17 18 19 20 21	A. Okay. So as I recall sitting here today, the estimated nonwrapped potential exposure beyond 2013 represented estimated lifetime losses, which I'm testing with the note here, multiplied by risks post fund audit defect rates adjusted for litigation defenses. Risk referred to Todd Kushman's group. And so that would have been what I don't remember is nonwrapped potential exposure beyond 2013, whether that would have included anything beyond private label securities nonwrapped potential exposure. I just don't remember. Q. The next line under Additional Items says "Adj. for application of defect rate at a nonloan level for nonwrapped PLS and additional provision for wrapped PLS." Do you see that? A. I see it, yeah.	234567890112345678901 112345678901	TIMOTHY DEVINE investor/securities litigation." And there's a \$400 million number next to that. Wasn't that some estimate of the possible or reasonably possible range of loss for securities litigation? MR. BRYAN: Object to form. A. Yeah. Well, there's a lot of detail behind that line. And as I sit here today, I just can't remember the detail. But as I recall, that would have been a number subject to a variety of stresses that were imposed on the process from outside of this sort of legal advisory function. Q. Right. Okay. A. That's the more complete answer. Q. Let me show you what's been marked previously as Exhibit 83. A. Thank you. Q. Which is an e-mail chain on May
2 3 4 5 6 7 8 9 10 11 2 13 14 15 6 17 18 19 20 21 22 22	A. Okay. So as I recall sitting here today, the estimated nonwrapped potential exposure beyond 2013 represented estimated lifetime losses, which I'm testing with the note here, multiplied by risks post fund audit defect rates adjusted for litigation defenses. Risk referred to Todd Kushman's group. And so that would have been what I don't remember is nonwrapped potential exposure beyond 2013, whether that would have included anything beyond private label securities nonwrapped potential exposure. I just don't remember. Q. The next line under Additional Items says "Adj. for application of defect rate at a nonloan level for nonwrapped PLS and additional provision for wrapped PLS." Do you see that? A. I see it, yeah. Q. And that shows an adjustment of	23456789011234567890122 22222	TIMOTHY DEVINE investor/securities litigation." And there's a \$400 million number next to that. Wasn't that some estimate of the possible or reasonably possible range of loss for securities litigation? MR. BRYAN: Object to form. A. Yeah. Well, there's a lot of detail behind that line. And as I sit here today, I just can't remember the detail. But as I recall, that would have been a number subject to a variety of stresses that were imposed on the process from outside of this sort of legal advisory function. Q. Right. Okay. A. That's the more complete answer. Q. Let me show you what's been marked previously as Exhibit 83. A. Thank you. Q. Which is an e-mail chain on May 4, 2012. There are two e-mails in this
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. Okay. So as I recall sitting here today, the estimated nonwrapped potential exposure beyond 2013 represented estimated lifetime losses, which I'm testing with the note here, multiplied by risks post fund audit defect rates adjusted for litigation defenses. Risk referred to Todd Kushman's group. And so that would have been what I don't remember is nonwrapped potential exposure beyond 2013, whether that would have included anything beyond private label securities nonwrapped potential exposure. I just don't remember. Q. The next line under Additional Items says "Adj. for application of defect rate at a nonloan level for nonwrapped PLS and additional provision for wrapped PLS." Do you see that? A. I see it, yeah. Q. And that shows an adjustment of \$500 million upwards for nonwrapped and	23456789012345678901223	TIMOTHY DEVINE investor/securities litigation." And there's a \$400 million number next to that. Wasn't that some estimate of the possible or reasonably possible range of loss for securities litigation? MR. BRYAN: Object to form. A. Yeah. Well, there's a lot of detail behind that line. And as I sit here today, I just can't remember the detail. But as I recall, that would have been a number subject to a variety of stresses that were imposed on the process from outside of this sort of legal advisory function. Q. Right. Okay. A. That's the more complete answer. Q. Let me show you what's been marked previously as Exhibit 83. A. Thank you. Q. Which is an e-mail chain on May 4, 2012. There are two e-mails in this exhibit. Did you receive the one from
2 3 4 5 6 7 8 9 0 11 12 13 14 15 6 17 18 9 20 12 21 22 22 22 22 22 22 22 22 22 22 22	A. Okay. So as I recall sitting here today, the estimated nonwrapped potential exposure beyond 2013 represented estimated lifetime losses, which I'm testing with the note here, multiplied by risks post fund audit defect rates adjusted for litigation defenses. Risk referred to Todd Kushman's group. And so that would have been what I don't remember is nonwrapped potential exposure beyond 2013, whether that would have included anything beyond private label securities nonwrapped potential exposure. I just don't remember. Q. The next line under Additional Items says "Adj. for application of defect rate at a nonloan level for nonwrapped PLS and additional provision for wrapped PLS." Do you see that? A. I see it, yeah. Q. And that shows an adjustment of	23456789011234567890122 22222	TIMOTHY DEVINE investor/securities litigation." And there's a \$400 million number next to that. Wasn't that some estimate of the possible or reasonably possible range of loss for securities litigation? MR. BRYAN: Object to form. A. Yeah. Well, there's a lot of detail behind that line. And as I sit here today, I just can't remember the detail. But as I recall, that would have been a number subject to a variety of stresses that were imposed on the process from outside of this sort of legal advisory function. Q. Right. Okay. A. That's the more complete answer. Q. Let me show you what's been marked previously as Exhibit 83. A. Thank you. Q. Which is an e-mail chain on May 4, 2012. There are two e-mails in this

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

TIMOTHY DEVINE

1

2

3

4

5

6

7

8

9

0

1

2

.3

4

5

6

17

8

L 9

20

21

22

23

24

25

don't remember sitting here today what the ultimate timing of a deal was, when hands were shaken on final language. I'm kind of eager to see where that -- where that goes and where it ends. I wonder how close we were at May 9th at 10:05. But I will tell you that I was, I had a sense that a deal was doable and I didn't want anything getting in the way of the essential deal as I had understood it to take shape.

So if somebody told me at some time before 10:05 on Wednesday, May 9th somebody was throwing a curve ball setoff or otherwise into the negotiations I may well have taken the time to figure out what they were talking about in consultation with my counsel. If it was too complicated or irrelevant to what my self understood scope was, maybe I listened and maybe I got half or more of it. I did recognize it as a potential obstacle of getting a deal done and so I was not ready to allow it to become part

TIMOTHY DEVINE

favorable and fair to all concerned and I wanted to get the deal done as I understood we were on a certain timeline.

- Q. Looking at the top e-mail in the chain from Mr. Lee to yourself, among others, at 10:54 a.m. on May 9th, did you receive that e-mail?
 - A. It looks like I did, yes.
- Q. And Mr. Lee wrote, "We will be seeking ResCap board approval today. Does Ally's board need to approve as it is signing the PSA and ResCap is agreeing to settle a claim in excess of 25 million, which requires Ally approval under Ally's governance framework. Please let us know."

Did AFI's board need to approve?

- A. I don't know.
- Q. Did Mr. Lee, to your knowledge, receive a response to his inquiry?
 - A. I don't know.
- Q. Does Mr. Lee's reference to the ResCap board -- his reference to seeking ResCap board approval today, meaning

	Pg 6 01 6		
	270		272
1	TIMOTHY DEVINE	1	TIMOTHY DEVINE
2	party to the agreement has or may have at	2	release because that is the full extent of
3	any time up to and including the date of	3	her representation. She has been clear
4	the release.	4	about that. Same as in her" BofA "B of
5	Q. Did you intend to include within	5	New York Mellon work, etc."
6	the word "everything" claims that might be	6	Do you see that?
7	asserted by any of the monolines?	7	A. Yes, I do see that.
8	A. My understanding at the time was	8	Q. And then you said "But notice,
9	that the monolines would participate and	9	though her clients don't release
10	were contemplated to participate in the	10	securities claims, they sign plan support
11	settlement.	11	agreements and the plan includes very
12	Q. But by May 10th the settlement	12	simple comprehensive releases, which of
13	was already signed up, wasn't it?	13	course include third-party release of all
14	MR. PRINCI: Objection as to	14	claims which of course includes securities
15	form.	15	claims. Presto. So while she can't
16	A. I don't know.	16	represent parties in giving up their
17	Q. Okay. Let's put it this way.	17	securities claims, clients face a choice,
18	You knew it had been approved by the	18	either sign up with the settlement to make
19	ResCap board, didn't you?	19	sure your trust receives monies under the
20	A. No.	20	waterfall in which case you need to sign
21	Q. You didn't?	21	the plan support agreement and support the
22	A. No.	22	plan. And the plan wipes out all their
23	Q. So when you said everything in	23	claims of any sort. This is the beauty of
24	this e-mail, did you intend or not intend	24	it."
25	to include a release by the monolines of	25	Do you see that?
	271		273
1	TIMOTHY DEVINE	1	TIMOTHY DEVINE
2	their claims?	2	A. I see that.
3	MR. BRYAN: Object to form. I	3	Q. So you were explaining how
4	knew I certainly knew that the		
	KIICW I CEITAIIIIV KIICW HIAI HIE	1 /1	execution of the plan support agreement
		4 5	execution of the plan support agreement
5	monolines were not a signatory party	5	achieved releases of securities claims
5 6	monolines were not a signatory party to the settlement. But it was my	5 6	achieved releases of securities claims even if the settlement agreement itself
5 6 7	monolines were not a signatory party to the settlement. But it was my understanding that the claims that	5 6 7	achieved releases of securities claims even if the settlement agreement itself did not, correct?
5 6 7 8	monolines were not a signatory party to the settlement. But it was my understanding that the claims that they would or could enunciate in	5 6 7 8	achieved releases of securities claims even if the settlement agreement itself did not, correct? A. What I was explaining is that in
5 6 7 8 9	monolines were not a signatory party to the settlement. But it was my understanding that the claims that they would or could enunciate in connection with the securities subject	5 6 7 8 9	achieved releases of securities claims even if the settlement agreement itself did not, correct? A. What I was explaining is that in signing up for the settlement agreement
5 6 7 8 9	monolines were not a signatory party to the settlement. But it was my understanding that the claims that they would or could enunciate in connection with the securities subject of the settlement would be included	5 6 7 8 9	achieved releases of securities claims even if the settlement agreement itself did not, correct? A. What I was explaining is that in signing up for the settlement agreement between ResCap and with ResCap those
5 6 7 8 9 10	monolines were not a signatory party to the settlement. But it was my understanding that the claims that they would or could enunciate in connection with the securities subject of the settlement would be included within the scope of the allowed claim.	5 6 7 8 9 10 11	achieved releases of securities claims even if the settlement agreement itself did not, correct? A. What I was explaining is that in signing up for the settlement agreement between ResCap and with ResCap those parties were committing to sign a plan
5 6 7 8 9 10 11	monolines were not a signatory party to the settlement. But it was my understanding that the claims that they would or could enunciate in connection with the securities subject of the settlement would be included within the scope of the allowed claim. Q. You said, "And we can define	5 6 7 8 9 10 11	achieved releases of securities claims even if the settlement agreement itself did not, correct? A. What I was explaining is that in signing up for the settlement agreement between ResCap and with ResCap those parties were committing to sign a plan support agreement simultaneously, which to
5 6 7 8 9 10 11 12	monolines were not a signatory party to the settlement. But it was my understanding that the claims that they would or could enunciate in connection with the securities subject of the settlement would be included within the scope of the allowed claim. Q. You said, "And we can define securities claims narrowly." What do you	5 6 7 8 9 10 11 12	achieved releases of securities claims even if the settlement agreement itself did not, correct? A. What I was explaining is that in signing up for the settlement agreement between ResCap and with ResCap those parties were committing to sign a plan support agreement simultaneously, which to my understanding represented their
5 6 7 8 9 10 11 12 13 14	monolines were not a signatory party to the settlement. But it was my understanding that the claims that they would or could enunciate in connection with the securities subject of the settlement would be included within the scope of the allowed claim. Q. You said, "And we can define securities claims narrowly." What do you mean by that?	5 6 7 8 9 10 11 12 13	achieved releases of securities claims even if the settlement agreement itself did not, correct? A. What I was explaining is that in signing up for the settlement agreement between ResCap and with ResCap those parties were committing to sign a plan support agreement simultaneously, which to my understanding represented their valuation of the securities claims they
5 6 7 8 9 10 11 12 13 14 15	monolines were not a signatory party to the settlement. But it was my understanding that the claims that they would or could enunciate in connection with the securities subject of the settlement would be included within the scope of the allowed claim. Q. You said, "And we can define securities claims narrowly." What do you mean by that? A. What I meant by securities	5 6 7 8 9 10 11 12 13 14 15	achieved releases of securities claims even if the settlement agreement itself did not, correct? A. What I was explaining is that in signing up for the settlement agreement between ResCap and with ResCap those parties were committing to sign a plan support agreement simultaneously, which to my understanding represented their valuation of the securities claims they were giving up and therefore they were
5 6 7 8 9 10 11 12 13 14 15 16	monolines were not a signatory party to the settlement. But it was my understanding that the claims that they would or could enunciate in connection with the securities subject of the settlement would be included within the scope of the allowed claim. Q. You said, "And we can define securities claims narrowly." What do you mean by that? A. What I meant by securities claims was claims brought by securities	5 6 7 8 9 10 11 12 13 14 15	achieved releases of securities claims even if the settlement agreement itself did not, correct? A. What I was explaining is that in signing up for the settlement agreement between ResCap and with ResCap those parties were committing to sign a plan support agreement simultaneously, which to my understanding represented their valuation of the securities claims they were giving up and therefore they were supporting a plan which would include
5 6 7 8 9 10 11 12 13 14 15 16 7	monolines were not a signatory party to the settlement. But it was my understanding that the claims that they would or could enunciate in connection with the securities subject of the settlement would be included within the scope of the allowed claim. Q. You said, "And we can define securities claims narrowly." What do you mean by that? A. What I meant by securities claims was claims brought by securities holders on traditional federal securities	5 6 7 8 9 10 11 12 13 14 15 16 17	achieved releases of securities claims even if the settlement agreement itself did not, correct? A. What I was explaining is that in signing up for the settlement agreement between ResCap and with ResCap those parties were committing to sign a plan support agreement simultaneously, which to my understanding represented their valuation of the securities claims they were giving up and therefore they were supporting a plan which would include release of securities claims against the
5 6 7 8 9 10 11 12 13 14 15 16 7 18	monolines were not a signatory party to the settlement. But it was my understanding that the claims that they would or could enunciate in connection with the securities subject of the settlement would be included within the scope of the allowed claim. Q. You said, "And we can define securities claims narrowly." What do you mean by that? A. What I meant by securities claims was claims brought by securities holders on traditional federal securities law or state blue sky or the closely	5 6 7 8 9 10 11 12 13 14 15 16 17 18	achieved releases of securities claims even if the settlement agreement itself did not, correct? A. What I was explaining is that in signing up for the settlement agreement between ResCap and with ResCap those parties were committing to sign a plan support agreement simultaneously, which to my understanding represented their valuation of the securities claims they were giving up and therefore they were supporting a plan which would include release of securities claims against the debtor and release of securities claims,
5 6 7 8 9 0 1 1 2 3 4 1 5 1 6 7 1 8 9 1 1 2 3 4 1 5 1 6 7 1 8 9 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	monolines were not a signatory party to the settlement. But it was my understanding that the claims that they would or could enunciate in connection with the securities subject of the settlement would be included within the scope of the allowed claim. Q. You said, "And we can define securities claims narrowly." What do you mean by that? A. What I meant by securities claims was claims brought by securities holders on traditional federal securities law or state blue sky or the closely Allied state common law fraud claims that	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	achieved releases of securities claims even if the settlement agreement itself did not, correct? A. What I was explaining is that in signing up for the settlement agreement between ResCap and with ResCap those parties were committing to sign a plan support agreement simultaneously, which to my understanding represented their valuation of the securities claims they were giving up and therefore they were supporting a plan which would include release of securities claims against the debtor and release of securities claims, such as they might be, against Ally
5 6 7 8 9 0 1 1 2 1 3 4 1 5 6 7 8 9 0 1 2 2 3 4 5 1 7 1 8 9 2 0	monolines were not a signatory party to the settlement. But it was my understanding that the claims that they would or could enunciate in connection with the securities subject of the settlement would be included within the scope of the allowed claim. Q. You said, "And we can define securities claims narrowly." What do you mean by that? A. What I meant by securities claims was claims brought by securities holders on traditional federal securities law or state blue sky or the closely Allied state common law fraud claims that would be characterized typically as a	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	achieved releases of securities claims even if the settlement agreement itself did not, correct? A. What I was explaining is that in signing up for the settlement agreement between ResCap and with ResCap those parties were committing to sign a plan support agreement simultaneously, which to my understanding represented their valuation of the securities claims they were giving up and therefore they were supporting a plan which would include release of securities claims against the debtor and release of securities claims, such as they might be, against Ally Financial.
5 6 7 8 9 0 1 1 2 1 3 4 1 5 6 7 8 9 0 2 1	monolines were not a signatory party to the settlement. But it was my understanding that the claims that they would or could enunciate in connection with the securities subject of the settlement would be included within the scope of the allowed claim. Q. You said, "And we can define securities claims narrowly." What do you mean by that? A. What I meant by securities claims was claims brought by securities holders on traditional federal securities law or state blue sky or the closely Allied state common law fraud claims that would be characterized typically as a securities based claim.	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 21	achieved releases of securities claims even if the settlement agreement itself did not, correct? A. What I was explaining is that in signing up for the settlement agreement between ResCap and with ResCap those parties were committing to sign a plan support agreement simultaneously, which to my understanding represented their valuation of the securities claims they were giving up and therefore they were supporting a plan which would include release of securities claims against the debtor and release of securities claims, such as they might be, against Ally Financial. Q. And you thought that was pretty
5 6 7 8 9 10 11 2 13 14 15 6 7 18 9 20 1 22 22	monolines were not a signatory party to the settlement. But it was my understanding that the claims that they would or could enunciate in connection with the securities subject of the settlement would be included within the scope of the allowed claim. Q. You said, "And we can define securities claims narrowly." What do you mean by that? A. What I meant by securities claims was claims brought by securities holders on traditional federal securities law or state blue sky or the closely Allied state common law fraud claims that would be characterized typically as a securities based claim. Q. A bit further down in your	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	achieved releases of securities claims even if the settlement agreement itself did not, correct? A. What I was explaining is that in signing up for the settlement agreement between ResCap and with ResCap those parties were committing to sign a plan support agreement simultaneously, which to my understanding represented their valuation of the securities claims they were giving up and therefore they were supporting a plan which would include release of securities claims against the debtor and release of securities claims, such as they might be, against Ally Financial. Q. And you thought that was pretty clever, didn't you?
5 6 7 8 9 0 1 1 2 1 3 1 4 1 5 6 7 1 8 9 0 2 2 2 3	monolines were not a signatory party to the settlement. But it was my understanding that the claims that they would or could enunciate in connection with the securities subject of the settlement would be included within the scope of the allowed claim. Q. You said, "And we can define securities claims narrowly." What do you mean by that? A. What I meant by securities claims was claims brought by securities holders on traditional federal securities law or state blue sky or the closely Allied state common law fraud claims that would be characterized typically as a securities based claim. Q. A bit further down in your e-mail you said "The circle is squared at	5 6 7 8 9 0 11 12 13 14 15 16 17 18 9 20 21 22 23	achieved releases of securities claims even if the settlement agreement itself did not, correct? A. What I was explaining is that in signing up for the settlement agreement between ResCap and with ResCap those parties were committing to sign a plan support agreement simultaneously, which to my understanding represented their valuation of the securities claims they were giving up and therefore they were supporting a plan which would include release of securities claims against the debtor and release of securities claims, such as they might be, against Ally Financial. Q. And you thought that was pretty clever, didn't you? MR. BRYAN: Object to form.
5 6 7 8 9 10 11 12 13 14 15 16 7 18 18 20 21 22	monolines were not a signatory party to the settlement. But it was my understanding that the claims that they would or could enunciate in connection with the securities subject of the settlement would be included within the scope of the allowed claim. Q. You said, "And we can define securities claims narrowly." What do you mean by that? A. What I meant by securities claims was claims brought by securities holders on traditional federal securities law or state blue sky or the closely Allied state common law fraud claims that would be characterized typically as a securities based claim. Q. A bit further down in your	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	achieved releases of securities claims even if the settlement agreement itself did not, correct? A. What I was explaining is that in signing up for the settlement agreement between ResCap and with ResCap those parties were committing to sign a plan support agreement simultaneously, which to my understanding represented their valuation of the securities claims they were giving up and therefore they were supporting a plan which would include release of securities claims against the debtor and release of securities claims, such as they might be, against Ally Financial. Q. And you thought that was pretty clever, didn't you?